Pharmacoeconomics for migraine and headache researchers: Basic concepts, methods and terminology

Journal of Headache and Pain

Volumn 5, Issue 4, 2004, Pages 217-223

  Walley, Tom ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Evaluation; Health economics; Methods; Migraine; Pharmaceuticals

Indexed keywords

ALMOTRIPTAN; ANTIMIGRAINE AGENT; ELETRIPTAN; PARACETAMOL; RIZATRIPTAN; SUMATRIPTAN;

ACUTE DRUG ADMINISTRATION; CHRONIC DRUG ADMINISTRATION; CONCEPT FORMATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEADACHE; HEALTH ECONOMICS; HUMAN; MEDICAL CARE; MEDICAL RESEARCH; METHODOLOGY; MIGRAINE; NOMENCLATURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESOURCE MANAGEMENT; REVIEW; SIDE EFFECT;

EID: 11244326820     PISSN: 11292369     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10194-004-0129-y     Document Type: Review

References (28)

1. Mossialos E, Mrazek M, Walley T (eds) (2004) Regulating pharmaceuticals in Europe: Striving to improving efficiency, quality and equity while containing costs. Open University Press, London
2. Walley T, Haycox A, Boland A (eds) Pharmacoeconomics. Churchill Livingstone, Edinburgh
3. Walley T (1995) Drugs, money and society. Br J Clin Pharmacol 39:343-345
4. Langley P (2004) Focusing pharmacoeconomic activities: Reimbursement or the drug life cycle? Curr Med Res Opin 20:181-188
5. Raftery J (2001) NICE: Faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323:1300-1303
6. Lofland JH, Kim SS, Batenhorst AS, Johnson NE, Chatterton ML, Cady RK, Kaniecki R, Nash DB (2001) Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc 76:1093-1101
7. Wells N, Hettiarachchi J, Drummond M, Carter D, Parpia T, Pang F (2003) A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health 6:438-447
8. Terwindt GM, Ferrari MD, Tijhuis M et al (2000) The impact of migraine on quality of life in the general population; the GEM study. Neurology 55:624-629
9. Turner-Bowker DM, Bayliss MS, Ware JE Jr, Kosinski M (2003) Usefulness of the SF-8 Health Survey for comparing the impact of migraine and other conditions. Qual Life Res 12:1003-1012
10. Caro JJ, Getsios D (2002) Pharmacoeconomic evidence and considerations for triptan treatment of migraine. Expert Opin Pharmacother 3:237-248
11. Adelman JU, Adelman LC, Freeman MC, Von Seggern RL, Drake J (2004) Cost considerations of acute migraine treatment. Headache 44:271-285
12. Williams P, Reeder CE (2004) A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm 10:259-265
13. Williams P, Reeder CE (2003) Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clin Ther 25(11):2903-2919
14. Adelman JU, Belsey J (2003) Metaanalysis of oral triptan therapy for migraine: Number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 9:45-52
15. Reeder CE, Steadman S, Goldfarb SD (2002) Economic comparison of oral triptans for management of acute migraine: Implications for managed care. Am J Manag Care 8[Suppl]:S80-S84
16. Belsey JD (2004) Cost effectiveness of oral triptan therapy: A trans-national comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 20:659-669
17. Wonderling D, Vickers AJ, Grieve R, McCarney R (2004) Cost effectiveness analysis of a randomised trial of acupuncture for chronic headache in primary care. BMJ 328:747
18. Gerth WC, Sarma S, Hu XH, Silberstein SD (2004) Productivity cost benefit to employers of treating migraine with rizatriptan: A specific worksite analysis and model. J Occup Environ Med 46:48-54
19. Biddle AK, Shih YC, Kwong WJ (2000) Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 20:1356-1364
20. Lipton RB, Stewart WF, Scher AI (2001) Epidemiology and economic impact of migraine. Curr Med Res Opin 17[Suppl 1]:s4-s12
21. Burton W, Conti D, Chen C, Schultz A,Edington D (2002) The economic burden of lost productivity due to migraine: A specific worksite analysis. J Occup Environ Med 44:523-529
22. Edmeads J, Mackell JA (2002) The economic impact of migraine: An analysis of direct and indirect costs. Headache 42:501-509
23. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 159:813-818
24. Pesa J, Lage MJ (2004) The medical costs of migraine and comorbid anxiety and depression. Headache 44:562-570
25. Smith DG (2003) Cost-effectiveness of migraine treatment: A commentary. Value Health 6:438-447
26. Cull R, Wells N, Miocevick M (1992) Economic costs of migraine. Br J Med Econ 5:103-115
27. Drummond MF (1992) Economic evaluation of pharmaceuticals: Marketing or science? Pharmacoeconomics 1:8-13
28. Sacristan JA, Bolanos E, Hernandez JM, Soto J, Galende I (1997) Publication bias in health economic studies. Pharmacoeconomics 11:289-292